First Trust Advisors LP grew its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 319.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 186,300 shares of the life sciences company's stock after purchasing an additional 141,907 shares during the quarter. First Trust Advisors LP owned about 0.24% of Integra LifeSciences worth $4,225,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Quadrant Capital Group LLC increased its stake in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the period. Sterling Capital Management LLC grew its position in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after buying an additional 1,931 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after buying an additional 2,800 shares during the period. Covestor Ltd boosted its stake in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after acquiring an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Integra LifeSciences during the 4th quarter worth $180,000. Institutional investors own 84.78% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. Truist Financial cut their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. JPMorgan Chase & Co. cut their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday. Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday. Finally, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $19.88.
Check Out Our Latest Stock Report on IART
Integra LifeSciences Stock Down 4.0 %
Shares of NASDAQ:IART traded down $0.53 during trading on Tuesday, hitting $12.75. 2,558,672 shares of the company's stock traded hands, compared to its average volume of 1,073,279. The company has a 50-day moving average price of $19.73 and a 200-day moving average price of $22.09. Integra LifeSciences Holdings Co. has a 52 week low of $11.60 and a 52 week high of $32.66. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market cap of $984.94 million, a price-to-earnings ratio of -141.65, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same period in the previous year, the firm posted $0.55 EPS. The business's quarterly revenue was up 3.7% compared to the same quarter last year. As a group, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.
About Integra LifeSciences
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Read More
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
